It's an excellent opportunity to buy shares of what could become a biotech giant on the dip.
An investment in these players today could score a big win down the road.
Investing tips from Bill Mann, The Motley Fool's director of small-cap research.
Is the potential upside for CRISPR Therapeutics too massive to ignore?
These companies are nearly in the sweet spot of risk versus reward in biotech.
Losses for several big technology companies pulled the stock market lower
The companies are chasing major innovations.
A federal appeals court has revived an antitrust lawsuit the District of Columbia brought against Amazon
You aren't powerless in the face of what the market throws at you.
Shares of the rare disease drugmaker are already up more than 40% over the past year.